BIAL attended the 32th International Epilepsy Congress where the most recent data, studies and therapeutics within the area of Epilepsy were discussed. 20 posters on the eslicarbazepine acetate were presented, the first medicine of BIAL’s own research and development for Epilepsy.
More than 3200 people attended this congress, the most important one on Epilepsy in Europe.
BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.
